German medicines giant Bayer mentioned Monday it had launched tests into an injectable drug to fight the fat deposits that result in the dreaded "double chin."
Bayer stated in a very statement it was conducting medical trials into ATX-101, an injectable drug "for the reduction of localised fat under the chin (submental extra fat)."
The firm is testing some 720 individuals in 64 centres in Britain, France, Germany, Belgium, Spain and Italy having a view to launching a product in Europe, Asia and South America in 2014.
Jean-Paul Ortonne, a French dermatologist involved in the trials, said: "There is a massive demand for any secure, effective and authorized injectable therapy for localised excess fat reduction."
The assessments are a step towards "a well-studied, clinically-proven therapy to reduce localised submental fat with out surgical treatment," he additional.
Yvonne Moeller, a Bayer spokeswoman, described the process as "something like a tattoo."
Between forty and 70 tiny injections are administered in to the fat cells more than numerous periods, with the amount according to the size from the double chin along with the person, she told AFP.
"You would hope to see obvious outcomes after about 16 weeks," she extra.
Use the following link to trackback from your own site: